We provide you with 20 years of free, institutional-grade data for BMEA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BMEA. Explore the full financial landscape of BMEA stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Valle Franco | Grant, award...etc | 1,345 | $3.78 | 2023-12-01 | |
| A2A Pharmaceuticals, Inc. | Sale | -125,000 | $33.81 | $4,226,250 | 2023-06-02 |
| Valle Franco | Grant, award...etc | 4,273 | $3.78 | 2023-06-02 | |
| A2A Pharmaceuticals, Inc. | Sale | -25,000 | $33.84 | $846,000 | 2023-05-17 |
| A2A Pharmaceuticals, Inc. | Sale | -250,000 | $33.99 | $8,498,275 | 2023-05-10 |
| A2A Pharmaceuticals, Inc. | Sale | -200,000 | $29.12 | $5,823,760 | 2023-04-26 |
| A2A Pharmaceuticals, Inc. | Sale | 0 | $31.25 | 2023-04-06 | |
| Chen Bihua | Open Market Purchase | 400,000 | $30 | 2023-04-03 | |
| Erdtmann Rainer M | Open Market Purchase | 3,000 | $17 | 2023-02-10 | |
| Erdtmann Rainer M | Open Market Purchase | 5,400 | $17 | 2023-02-10 | |
| Valle Franco | Grant, award...etc | 2,518 | $3.78 | 2022-12-02 | |
| Hitchcock Michael J.M. | Open Market Purchase | 5,000 | $7.93 | 2022-11-16 | |
| Valle Franco | Open Market Purchase | 4,100 | $7.63 | 2022-11-14 | |
| A2A Pharmaceuticals, Inc. | Open Market Purchase | -30,684 | $13.87 | $425,648 | 2022-08-19 |
| A2A Pharmaceuticals, Inc. | Sale | -34,658 | $11.21 | $388,516 | 2022-07-25 |
| A2A Pharmaceuticals, Inc. | Sale | -34,658 | $11.76 | $407,578 | 2022-06-28 |
| Valle Franco | Grant, award...etc | 3,307 | $4.67 | 2022-06-01 | |
| Valle Franco | Open Market Purchase | 10,000 | $8.68 | 2022-01-18 | |
| A2A Pharmaceuticals, Inc. | Open Market Purchase | 34,658 | $10.96 | 2021-09-21 | |
| Stergiopoulos Sotirios | Open Market Purchase | 34,658 | $10.96 | 2021-09-21 | |
| Erdtmann Rainer M | Open Market Purchase | 24,000 | $13.2 | 2021-08-25 | |
| Butler Thomas Andrew | Open Market Purchase | 24,000 | $13.2 | 2021-08-25 | |
| Erdtmann Rainer M | Open Market Purchase | 204,470 | $17 | 2021-08-19 | |
| Butler Thomas Andrew | Open Market Purchase | 204,470 | $17 | 2021-08-19 | |
| A2A Pharmaceuticals, Inc. | Initial | 2021-04-26 | |||
| Chen Bihua | Open Market Purchase | 900,000 | $17 | 2021-04-22 | |
| Erdtmann Rainer M | Initial | 2021-04-15 | |||
| Butler Thomas Andrew | Initial | 2021-04-15 | |||
| Ryan Sunny | Initial | 2021-04-15 |
The information provided in this report about BMEA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Biomea Fusion, Inc.(NASDAQ:BMEA) 
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibit...
Website: http://www.biomeafusion.com
Founded: 2017
CEO: Thomas Butler
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends